Stay updated on ZUMA-2 Study Brexuca Clinical Trial

Sign up to get notified when there's something new on the ZUMA-2 Study Brexuca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ZUMA-2 Study Brexuca Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-14T01:58:53.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a new cohort (Cohort 3) has been added to the clinical study for participants with relapsed/refractory mantle cell lymphoma who have not received prior therapy with a BTKi, fulfilling an FDA Postmarketing Requirement.
    Difference
    0.1%
    Check dated 2024-06-06T16:02:07.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying up to 5 prior regimens for MCL and required prior therapies. This replaces the previous placeholder text indicating no information was provided.
    Difference
    18%
    Check dated 2024-05-22T12:40:04.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention possibly related to medical and healthcare publications and documentation.
    Difference
    1%
    Check dated 2024-05-01T15:49:35.000Z thumbnail image

Stay in the know with updates to ZUMA-2 Study Brexuca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ZUMA-2 Study Brexuca Clinical Trial page.